-
-
-
-
-
-
-
BioStem Technologies Announces the Publication of its Audited Financial Statements for Fiscal Years 2024 and 2025
-
-
-
-
-
-
-
BioStem Technologies Comments on Withdrawal of CMS CY 2026 Final Medicare Reimbursement Rule for Skin Substitutes
-
-
-
-
-
-
-
BioStem Technologies, Inc. (BSEM) Misses Q2 EPS by 131c
-
-
-
-
-
-
-
BioStem Technologies to Host First Quarter 2025 Financial Results Conference Call on May 12, 2025
-
-
-
-
-
-
-
BioStem Technologies to Report Third Quarter 2024 Financial Results on Tuesday, November 12, 2024
-
-
-
-
-
-
-
BioStem Technologies, Inc. (BSEM) Reports revenue
-
-
-
-
-
-
-
NovaBay Pharmaceuticals Announces Commercial Launch of Avenova® Allograft
-
1,222,642 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

